Litigation Details for Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA, Inc. (D. Del. 2016)
✉ Email this page to a colleague
Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA, Inc. (D. Del. 2016)
Docket | ⤷ Sign Up | Date Filed | 2016-04-08 |
Court | District Court, D. Delaware | Date Terminated | 2017-03-15 |
Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | None | Referred To | |
Patents | 6,328,994; 7,399,485; 7,431,942; 7,875,292 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA, Inc.
Details for Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA, Inc. (D. Del. 2016)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2016-04-08 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,328,994 B1; 7,431,942 B2; 7,875,292…2016 15 March 2017 1:16-cv-00246 830 Patent None District Court, D. Delaware | External link to document | |
2017-03-14 | 56 | infringes U.S. Patent No. 6,328,994 (“the ‘994 Patent”), U.S. Patent No. 7,431,942 (“the ‘942 Patent”), U.S.…U.S. Patent No. 7,875,292 (“the ‘292 Patent”), and U.S. Patent No. 7,399,485 (“the ‘485 Patent”) (collectively…collectively, the “Patents-in-Suit”) with respect to Teva’s Abbreviated New Drug Application (“ANDA”) No…non-infringement defenses and related counterclaims to the Patents-in-Suit; WHEREAS, in its Amended Answer… defenses and related counterclaims to the ‘994 Patent; WHEREAS, the Parties wish to resolve | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |